Cover Image
市場調查報告書

地中海型貧血的全球市場

Global Thalassemia Market: Industry Analysis & Outlook 2017-2021

出版商 Koncept Analytics 商品編碼 358800
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
地中海型貧血的全球市場 Global Thalassemia Market: Industry Analysis & Outlook 2017-2021
出版日期: 2017年12月20日 內容資訊: 英文 64 Pages
簡介

本報告提供地中海型貧血的治療方法的市場相關分析,疾病概要和治療方法,全球市場規模 (發病數量、治療費等),各地區的詳細趨勢,主要的推動及阻礙市場要素,企業間競爭現況,主要企業簡介等調查評估。

第1章 概要

  • 簡介
  • 地中海型貧血的種類
    • α地中海型貧血
    • β地中海型貧血
    • 鐮狀β地中海型貧血
  • 症狀和前兆
  • 治療選擇
    • 輸血
    • 骨髓移植

第2章 全球地中海型貧血市場

  • 全球地中海型貧血發病數量:重症度別
  • 全球地中海型貧血診斷數量:各類別
  • 全球輸血依賴性β地中海型貧血發病數量:各地區
  • 全球地中海型貧血市場:各治療法
    • 骨髓移植市場收益額
    • LentiGlobin BB305收益額
    • Luspatercept的收益額

第3章 各地區分析

  • 美國的地中海型貧血市場
    • 美國國內的β地中海型貧血攜帶者/患者人口
    • 美國國內的β地中海型貧血的重病患者人口
    • 美國國內的輸血依賴性β地中海型貧血的患者
    • 美國的親屬間的β地中海型貧血幹細胞移植
  • 歐洲的地中海型貧血市場
    • 歐洲的輸血依賴性β地中海型貧血患者數
    • 歐洲的輸血依賴性β地中海型貧血的重病/輕傷患者

第4章 市場動態

  • 成長推動因素
    • 醫療費用支出的擴大
    • 對幹細胞療法的研究開發 (R&D) 支出額的增額
    • 在東亞、太平洋各國的人口增加
  • 主要趨勢和動靜
    • 地中海型貧血治療的基因治療
    • 鐵螯合劑療法的進步
    • 胎兒血紅素的誘導物質
  • 課題
    • 亞太地區的未滿足需求
    • 高額的治療費
    • 替代性治療方法的缺乏

第5章 競爭環境

  • 骨髓移植療市場上競爭狀態
    • 全球主要企業的收益額比較
    • 全球主要企業的報酬率比較
    • 全球主要企業的市值比較
    • 美國的主要企業的收益額比較
  • 新的治療方法的競爭狀態
    • 新企業的產品平台比較

第6章 企業簡介

  • Lonza Group Ltd
    • 產業概要
    • 財務狀況
    • 產業策略
  • Bluebird Bio
  • Acceleron Pharma, Inc
  • Sangamo Biosciences

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two proteins called alpha globin and beta globin. A person inherits four genes to produce alpha globin protein and two genes to produce alpha globin protein from parents. Thalassemia is caused by any abnormality or mutation in one or more genes responsible for hemoglobin production. When a person inherits only one affected gene from parents then the person becomes a carrier of thalassemia. Since, thalassemia is an inherited disorder; one of the parents must be a carrier for thalassemia. When both the parents are carriers then the risk of giving birth to a thalassemia affected child is quite high. Thalassemia is generally of two types: alpha thalassemia and beta thalassemia.

Globally, thalassemia affects approximately 7% of the population and many of them are transfusion dependent patients. The global thalassemia market is likely to be driven with the growing market of bone marrow transplant and blood transfusion therapy, supported by high numbers of transfusion dependent patients.

The U.S. is expected to be the first region to start selling of thalassemia drugs due to developing drug pipeline and later on, market penetration of thalassemia drugs would occur in Europe. U.S. and Europe have high prevalence of severe forms of beta-thalassemia which would result into a high demand for thalassemia drugs in future.

The global thalassemia market is expected to grow in future with mounting prevalence of thalassemia, rising Asian population, increasing healthcare expenditure, rising spending on pharmaceuticals R&D and stem cell therapy research. Key trends of this market include progressing drug pipeline, rising scope for gene therapy and growing awareness towards thalassemia. However, there are some factors which can hinder growth of the market including regulatory changes, associated risks and high cost of treatment.

The report "Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)" by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering U.S, and Europe along with the global market. The report profiles key players of the market including GlaxoSmithKline Plc, Celgene, Bluebird Bio and Bellicum Pharmaceuticals.

Table of Contents

1. Introduction

  • 1.1 Thalassemia
  • 1.2 Types of Thalassemia
  • 1.3 Diagnosis and Treatment

2. Global Thalassemia Market

  • 2.1 Thalassemia Population by Category
  • 2.2 Thalassemia Market by Treatment
    • 2.2.1 Global Bone Marrow Market Forecast by Value
    • 2.2.2 Global Luspatercept Revenue Forecast for Beta-Thalassemia

3. Regional Market Analysis

  • 3.1 The U.S.
    • 3.1.1 The U.S. Beta-Thalassemia Patient Volume Forecast
    • 3.1.2 The U.S. Beta-Thalassemia Intermedia/Major Patient Volume Forecast
    • 3.1.3 The U.S. Beta-Thalassemia Intermedia/Major Patient Volume by Category
    • 3.1.4 The U.S. Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast
    • 3.1.5 The U.S. Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast
    • 3.1.6 The U.S. Luspatercept Drug Revenue Forecast for Beta-Thalassemia
  • 3.2 Europe
    • 3.2.1 Europe Beta-Thalassemia Patient Volume Forecast
    • 3.2.2 Europe Beta-Thalassemia Intermedia/Major Patient Volume Forecast
    • 3.2.3 Europe Beta-Thalassemia Intermedia/Major Patient Volume by Category
    • 3.2.4 Europe Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast
    • 3.2.5 Europe Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast
    • 3.2.6 Europe Luspatercept Drug Revenue Forecast for Beta-Thalassemia

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Mounting Prevalence of Thalassemia
    • 4.1.2 Increasing Pharmaceutical R&D Spending
    • 4.1.3 Increasing Spending on Stem Cell Research
    • 4.1.4 Rising Healthcare Expenditure
    • 4.1.5 Rising Asian Population
  • 4.2 Key Trends & Developments
    • 4.2.1 Progressing Drugs under Pipeline
    • 4.2.2 Rising Scope for Gene Therapy
    • 4.2.3 Increasing Awareness towards Thalassemia
  • 4.3 Key Challenges
    • 4.3.1 Regulatory Challenges
    • 4.3.2 Other Associated Risks
    • 4.3.3 Highly Expensive Treatment

5. Competitive Landscape

  • 5.1 Global Market
    • 5.1.1 Revenue Comparison of Key Players
    • 5.1.2 Market Cap Comparison of Key Players

6. Company Profiles

  • 6.1 GlaxoSmithKline Plc.
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Celgene
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Bluebird Bio
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Bellicum Pharmaceuticals
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies

List of Charts

  • Types of Thalassemia
  • Global Thalassemia Population by Category (2016)
  • Global Bone Marrow Market Forecast by Value (2016-2021)
  • Global Luspatercept Revenue Forecast for Beta-Thalassemia (2019-2025)
  • The U.S. Beta-Thalassemia Patient Volume Forecast (2016-2021)
  • The U.S. Beta-Thalassemia Intermedia/Major Patient Volume Forecast (2016-2021)
  • The U.S. Beta-Thalassemia Intermedia/Major Patient Volume by Category (2016)
  • The U.S. Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast (2016-2021)
  • The U.S. Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast (2016-2021)
  • The U.S. Luspatercept Drug Revenue Forecast for Beta-Thalassemia (2019-2025)
  • Europe Beta-Thalassemia Patient Volume Forecast (2016-2021)
  • Europe Beta-Thalassemia Intermedia/Major Patient Volume Forecast (2016-2021)
  • Europe Beta-Thalassemia Intermedia/Major Patient Volume by Category (2016)
  • Europe Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast (2016-2021)
  • Europe Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast (2016-2021)
  • Europe Luspatercept Drug Revenue Forecast for Beta-Thalassemia (2020-2025)
  • Global Pharmaceutical R&D Spending (2013-2016)
  • NIH Spending on Stem Cell Research (2013-2016)
  • Global Healthcare Expenditure per Capita (2012-2016)
  • East Asia-Pacific Population (2012-2016)
  • Global Thalassemia Key Players - Revenue Comparison (2016)
  • Global Thalassemia Key Players - Market Cap Comparison (2016)
  • GlaxoSmithKline Plc. Revenue by Segment (2016)
  • GlaxoSmithKline Plc. Revenue (2012-2016)
  • GlaxoSmithKline Plc. R&D Expenditure (2014-2016)
  • Celgene Revenue by Region (2016)
  • Celgene Total Revenue and Net Income (2012-2016)
  • Celgene R&D Expenditure (2014-2016)
  • Bluebird Bio Revenue and Net Loss (2012-2016)
  • Bluebird Bio R&D Expenditure (2014-2016)
  • Bellicum Pharmaceuticals Revenue and Net Loss (2012-2016)
  • Bellicum Pharmaceuticals R&D Expenditure (2014-2016)

List of Tables

  • Drugs under Development for Thalassemia (2016)
  • Bluebird Bio's Product Pipeline
Back to Top